Published in Antimicrob Agents Chemother on March 09, 2009
Chromosomal mutations responsible for fluoroquinolone resistance in Ureaplasma species in the United States. Antimicrob Agents Chemother (2012) 1.05
Antimicrobial Susceptibility and Clonality of Clinical Ureaplasma Isolates in the United States. Antimicrob Agents Chemother (2016) 0.85
Antibiotic Susceptibility and Sequence Type Distribution of Ureaplasma Species Isolated from Genital Samples in Switzerland. Antimicrob Agents Chemother (2015) 0.82
Antibiotic Resistance among Clinical Ureaplasma Isolates Recovered from Neonates in England and Wales between 2007 and 2013. Antimicrob Agents Chemother (2015) 0.82
16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovis. Antimicrob Agents Chemother (2014) 0.81
Incidence and antibiotic susceptibility of genital mycoplasmas in sexually active individuals in Hungary. Eur J Clin Microbiol Infect Dis (2013) 0.81
Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection. Antimicrob Agents Chemother (2014) 0.79
Comparison of the new Mycofast Revolution assay with a molecular assay for the detection of genital mycoplasmas from clinical specimens. BMC Infect Dis (2013) 0.78
In vitro activity of five quinolones and analysis of the quinolone resistance-determining regions of gyrA, gyrB, parC, and parE in Ureaplasma parvum and Ureaplasma urealyticum clinical isolates from perinatal patients in Japan. Antimicrob Agents Chemother (2015) 0.77
Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum in asymptomatic women in Northern Greece. Hippokratia (2013) 0.75
Ureaplasma parvum genotype, combined vaginal colonisation with Candida albicans, and spontaneous preterm birth in an Australian cohort of pregnant women. BMC Pregnancy Childbirth (2016) 0.75
Random insertion and gene disruption via transposon mutagenesis of Ureaplasma parvum using a mini-transposon plasmid. Int J Med Microbiol (2014) 0.75
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med (2005) 7.15
The recovery of pleuropneumonia-like organisms from Negro men with and without nongonococcal urethritis. Am J Syph Gonorrhea Vener Dis (1954) 5.45
Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother (2000) 4.31
Crystal structure of the breakage-reunion domain of DNA gyrase. Nature (1997) 4.10
Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev (2005) 3.20
Dissemination of the tetM tetracycline resistance determinant to Ureaplasma urealyticum. Antimicrob Agents Chemother (1986) 3.08
The complete sequence of the mucosal pathogen Ureaplasma urealyticum. Nature (2000) 3.01
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother (2000) 3.00
Detection of Ureaplasma urealyticum by polymerase chain reaction in the urogenital tract of adults, in amniotic fluid, and in the respiratory tract of newborns. Clin Infect Dis (1993) 1.88
Ribosomal protein gene sequence changes in erythromycin-resistant mutants of Escherichia coli. J Bacteriol (1994) 1.85
The nucleotide sequence of the tetracycline resistance determinant tetM from Ureaplasma urealyticum. Nucleic Acids Res (1988) 1.77
Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob Agents Chemother (2000) 1.66
Increased intrauterine frequency of Ureaplasma urealyticum in women with preterm labor and preterm premature rupture of the membranes and subsequent cesarean delivery. Am J Obstet Gynecol (2005) 1.66
In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized. Antimicrob Agents Chemother (2000) 1.46
Ureaplasma urealyticum biovar specificity and diversity are encoded in multiple-banded antigen gene. J Clin Microbiol (1994) 1.42
Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J (2005) 1.33
DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones. Antimicrob Agents Chemother (2003) 1.31
Adverse outcome in pregnancy following amniotic fluid isolation of Ureaplasma urealyticum. Prenat Diagn (1992) 1.30
Fluoroquinolone resistance in Ureaplasma parvum in the United States. J Clin Microbiol (2006) 1.30
Comparative analysis and serovar-specific identification of multiple-banded antigen genes of Ureaplasma urealyticum biovar 1. J Clin Microbiol (1999) 1.23
Ureaplasma infection and neonatal lung disease. Semin Perinatol (2007) 1.18
Infection of the amniotic cavity with Ureaplasma urealyticum in the midtrimester of pregnancy. J Reprod Med (1995) 1.12
Tetracycline resistance in Ureaplasma spp. and Mycoplasma hominis: prevalence in Bordeaux, France, from 1999 to 2002 and description of two tet(M)-positive isolates of M. hominis susceptible to tetracyclines. Antimicrob Agents Chemother (2007) 1.11
Trends in the rates of resistance of Ureaplasma urealyticum to antibiotics and identification of the mutation site in the quinolone resistance-determining region in Chinese patients. FEMS Microbiol Lett (2006) 1.11
Vaginal Ureaplasma urealyticum colonization: influence on pregnancy outcome and neonatal morbidity. Infection (1997) 1.10
TetM tetracycline-resistant determinants in Ureaplasma urealyticum. Pediatr Infect Dis (1987) 1.08
Effect of pH, inoculum size, and incubation time on the susceptibility of Ureaplasma urealyticum to erythromycin in vitro. Clin Infect Dis (1993) 1.05
Antibiotic susceptibilities and therapeutic options for Ureaplasma urealyticum infections in neonates. Pediatr Infect Dis J (1992) 1.03
Study of isolation of fluoroquinolone-resistant Ureaplasma urealyticum and identification of mutant sites. Chin Med J (Engl) (2002) 1.02
Mechanisms of macrolide resistance in Ureaplasma urealyticum: a study on collection and clinical strains. Eur J Epidemiol (1989) 1.02
Therapeutic considerations for Ureaplasma urealyticum infections in neonates. Clin Infect Dis (1993) 1.00
Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents. Antimicrob Agents Chemother (1998) 0.99
Rapid detection of tetM in Mycoplasma hominis and Ureaplasma urealyticum by PCR: tetM confers resistance to tetracycline but not necessarily to doxycycline. FEMS Microbiol Lett (1992) 0.97
Characterization of tetracycline-resistant strains of Ureaplasma urealyticum. J Antimicrob Chemother (1988) 0.95
Ureaplasma urealyticum meningitis in an adult patient. J Clin Microbiol (2008) 0.95
Transition mutations in 23S rRNA account for acquired resistance to macrolides in Ureaplasma urealyticum. Microb Drug Resist (2008) 0.92
Characterisation of in vitro-selected mutants of Ureaplasma parvum resistant to macrolides and related antibiotics. Int J Antimicrob Agents (2006) 0.90
The macrolide binding site on the bacterial ribosome. Curr Drug Targets Infect Disord (2002) 0.90
Antenatal infection and inflammation: what's new? Curr Opin Infect Dis (2006) 0.88
The role of inflammation and infection in the development of chronic lung disease of prematurity. Adv Exp Med Biol (2006) 0.78
Prevalence and antibiotic susceptibility of Ureaplasma urealyticum in Malaysian neonates with respiratory distress. Med J Malaysia (1997) 0.77
Relationship between antenatal inflammation and antenatal infection identified by detection of microbial genes by polymerase chain reaction. Pediatr Res (2005) 1.70
VanT, a homologue of Vibrio harveyi LuxR, regulates serine, metalloprotease, pigment, and biofilm production in Vibrio anguillarum. J Bacteriol (2002) 1.43
Effect of preterm birth on later FEV1: a systematic review and meta-analysis. Thorax (2013) 1.36
The relevance of complement to virus biology. Virology (2004) 1.29
Real-time detection of Mycoplasma pneumoniae in respiratory samples with an internal processing control. J Med Microbiol (2006) 1.20
Lung growth and development. Early Hum Dev (2007) 1.20
Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors. J Virol (2005) 1.15
Spirometric lung function in school-age children: effect of intrauterine growth retardation and catch-up growth. Am J Respir Crit Care Med (2010) 1.14
Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation. Thorax (2013) 1.12
Effect of late preterm birth on longitudinal lung spirometry in school age children and adolescents. Thorax (2011) 1.11
The Kaposi's sarcoma-associated herpesvirus complement control protein (KCP) binds to heparin and cell surfaces via positively charged amino acids in CCP1-2. Mol Immunol (2006) 1.08
A novel hemotropic Mycoplasma (hemoplasma) in a patient with hemolytic anemia and pyrexia. Clin Infect Dis (2011) 1.05
Mapping CD55 function. The structure of two pathogen-binding domains at 1.7 A. J Biol Chem (2002) 1.05
A pilot investigation of mild hypothermia in neonates receiving extracorporeal membrane oxygenation (ECMO). J Pediatr (2004) 1.03
Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism. J Antimicrob Chemother (2009) 1.03
Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood (2010) 1.02
Respiratory distress of the term newborn infant. Paediatr Respir Rev (2012) 0.99
Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor. Circulation (2009) 0.98
Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line. J Virol (2011) 0.96
Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J Virol (2007) 0.94
Reproducibility of myocardial velocity and deformation imaging in term and preterm infants. Eur J Echocardiogr (2009) 0.93
Off to a slow start: under-development of the complement system in term newborns is more substantial following premature birth. Immunobiology (2011) 0.93
Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab Invest (2003) 0.92
Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. Kidney Int (2002) 0.92
Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice. J Infect Dis (2004) 0.91
The Kaposi's sarcoma-associated herpesvirus complement control protein mimics human molecular mechanisms for inhibition of the complement system. J Biol Chem (2004) 0.89
Serum killing of Ureaplasma parvum shows serovar-determined susceptibility for normal individuals and common variable immuno-deficiency patients. Immunobiology (2011) 0.89
Relationship of proteinases and proteinase inhibitors with microbial presence in chronic lung disease of prematurity. Thorax (2010) 0.89
Are early life factors considered when managing respiratory disease? A British Thoracic Society survey of current practice. Thorax (2012) 0.88
Antenatal infection and inflammation: what's new? Curr Opin Infect Dis (2006) 0.88
Exercise-induced bronchoconstriction in school-aged children who had chronic lung disease in infancy. J Pediatr (2012) 0.88
Synergic activation of toll-like receptor (TLR) 2/6 and 9 in response to Ureaplasma parvum & urealyticum in human amniotic epithelial cells. PLoS One (2013) 0.86
Cytokine imbalance in infants receiving extracorporeal membrane oxygenation for respiratory failure. Biol Neonate (2005) 0.86
Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP). J Biol Chem (2008) 0.85
Role of cytokines in hyperoxia mediated inflammation in the developing lung. Front Biosci (2003) 0.85
Inversion upstream of FOXF1 in a case of lethal alveolar capillary dysplasia with misalignment of pulmonary veins. Am J Med Genet A (2013) 0.84
Stability of lyophilised specimens for the molecular detection of viral DNA/RNA. J Clin Virol (2005) 0.84
Optimization of myocardial deformation imaging in term and preterm infants. Eur J Echocardiogr (2011) 0.84
Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis. Biochim Biophys Acta (2010) 0.83
Differential response of the epithelium and interstitium in developing human fetal lung explants to hyperoxia. Pediatr Res (2006) 0.83
Azithromycin, Ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development. Arch Dis Child (2011) 0.83
Acute lung injury in preterm newborn infants: mechanisms and management. Paediatr Respir Rev (2010) 0.82
Long term respiratory outcomes of late preterm-born infants. Semin Fetal Neonatal Med (2012) 0.82
Kaposi's sarcoma-associated herpes virus complement control protein: KCP--complement inhibition and more. Mol Immunol (2006) 0.82
Current practice for obtaining consent in UK neonatal units. Bull Med Ethics (2003) 0.81
Viral heparin-binding complement inhibitors--a recurring theme. Adv Exp Med Biol (2007) 0.81
Mechanism of neutrophil dysfunction: neutrophil serine proteases cleave and inactivate the C5a receptor. J Immunol (2014) 0.81
Association between pulmonary ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis. Pediatr Infect Dis J (2014) 0.81
Effect of bronchodilators on forced expiratory volume in 1 s in preterm-born participants aged 5 and over: a systematic review. Neonatology (2015) 0.80
More recent swine vesicular disease virus isolates retain binding to coxsackie-adenovirus receptor, but have lost the ability to bind human decay-accelerating factor (CD55). J Gen Virol (2005) 0.80
Susceptibility of B lymphocytes to adenovirus type 5 infection is dependent upon both coxsackie-adenovirus receptor and alphavbeta5 integrin expression. J Gen Virol (2005) 0.80
Role of interleukin-6, its receptor and soluble gp130 in chronic lung disease of prematurity. Neonatology (2013) 0.79
Trends in the incidence of severe retinopathy of prematurity in a geographically defined population over a 10-year period. Pediatrics (2004) 0.79
Molecular characterization of the rhesus rhadinovirus (RRV) ORF4 gene and the RRV complement control protein it encodes. J Virol (2007) 0.79
Prevalent human coxsackie B-5 virus infects porcine islet cells primarily using the coxsackie-adenovirus receptor. Xenotransplantation (2004) 0.79
Prevalence of Mycoplasma agassizii and Chelonian herpesvirus in captive tortoises (Testudo sp.) in the United Kingdom. J Zoo Wildl Med (2004) 0.78
Behavioural, educational and respiratory outcomes of antenatal betamethasone for term caesarean section (ASTECS trial). Arch Dis Child Fetal Neonatal Ed (2013) 0.78
Higher systolic blood pressure with normal vascular function measurements in preterm-born children. Acta Paediatr (2014) 0.78
The role of inflammation and infection in the development of chronic lung disease of prematurity. Adv Exp Med Biol (2006) 0.78
Detection of macrolide resistant Mycoplasma pneumoniae in England, September 2014 to September 2015. Euro Surveill (2015) 0.78
Human diffusely adhering Escherichia coli expressing Afa/Dr adhesins that use human CD55 (decay-accelerating factor) as a receptor does not bind the rodent and pig analogues of CD55. Infect Immun (2004) 0.78
High-resolution melt PCR analysis for genotyping of Ureaplasma parvum isolates directly from clinical samples. J Clin Microbiol (2013) 0.78
Perinatal outcomes and travel time from home to hospital: Welsh data from 1995 to 2009. Acta Paediatr (2014) 0.78
Growth characteristics of human adenoviruses on porcine cell lines. Virology (2008) 0.77
Assessment of pulmonary artery pulse wave velocity in children: an MRI pilot study. Magn Reson Imaging (2013) 0.77
Does Ureaplasma spp. cause chronic lung disease of prematurity: ask the audience? Early Hum Dev (2009) 0.77
Dynamic expression of IL-6 trans-signalling molecules in the lungs of preterm baboons undergoing mechanical ventilation. Neonatology (2011) 0.77
Management of infants with chronic lung disease of prematurity in the United Kingdom. Early Hum Dev (2005) 0.77
Separation of decay-accelerating and cofactor functional activities of Kaposi's sarcoma-associated herpesvirus complement control protein using monoclonal antibodies. Immunology (2007) 0.76
Long term cardiovascular consequences of chronic lung disease of prematurity. Paediatr Respir Rev (2012) 0.75
Integration of Genomic and Other Epidemiologic Data to Investigate and Control a Cross-Institutional Outbreak of Streptococcus pyogenes. Emerg Infect Dis (2016) 0.75
Monoclonal anti-neutrophil elastase antibody characterisation: ability to block function, detect free versus serpin-complexed enzyme and stain intracellular granules. J Immunol Methods (2008) 0.75
Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals. Vaccine (2007) 0.75
An optimal LC-MS/MS method for determination of azithromycin in white blood cells: application to pediatric samples. Bioanalysis (2014) 0.75
Long term respiratory outcomes of perinatal lung disease. Semin Fetal Neonatal Med (2012) 0.75
Serial bronchoalveolar lavage of preterm infants is not associated with chest radiological changes. Eur J Pediatr (2002) 0.75
Respiratory failure in a newborn infant. Arch Dis Child Educ Pract Ed (2007) 0.75